{"Title": "OV21/PETROC: A randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer", "Year": 2018, "Source": "Ann. Oncol.", "Volume": "29", "Issue": 2, "Art.No": null, "PageStart": 431, "PageEnd": 438, "CitedBy": 26, "DOI": "10.1093/annonc/mdx754", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85042559529&origin=inward", "Abstract": "\u00a9 The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.Background: The purpose of this multistage, adaptively, designed randomized phase II study was to evaluate the role of intraperitoneal (i.p.) chemotherapy following neoadjuvant chemotherapy (NACT) and optimal debulking surgery in women with epithelial ovarian cancer (EOC). Patients and methods: We carried out a multicenter, two-stage, phase II trial. Eligible patients with stage IIB-IVA EOC treated with platinum-based intravenous (i.v.) NACT followed by optimal (<1 cm) debulking surgery were randomized to one of the three treatment arms: (i) i.v. carboplatin/paclitaxel, (ii) i.p. cisplatin plus i.v./i.p. paclitaxel, or (iii) i.p. carboplatin plus i.v./i.p. paclitaxel. The primary end point was 9-month progressive disease rate (PD9). Secondary end points included progression-free survival (PFS), overall survival (OS), toxicity, and quality of life (QOL). Results: Between 2009 and 2015, 275 patients were randomized; i.p. cisplatin containing arm did not progress beyond the first stage of the study after failing to meet the pre-set superiority rule. The final analysis compared i.v. carboplatin/paclitaxel (n=101) with i.p. carboplatin, i.v./i.p. paclitaxel (n=102). The intention to treat PD9 was lower in the i.p. carboplatin arm compared with the i.v. carboplatin arm: 24.5% (95% CI 16.2% to 32.9%) versus 38.6% (95% CI 29.1% to 48.1%) P=0.065. The study was underpowered to detect differences in PFS: HR PFS 0.82 (95% CI 0.57-1.17); P=0.27 and OS HR 0.80 (95% CI 0.47-1.35) P=0.40. The i.p. carboplatin-based regimen was well tolerated with no reduction in QOL or increase in toxicity compared with i.v. administration alone. Conclusion: In women with stage IIIC or IVA EOC treated with NACT and optimal debulking surgery, i.p. carboplatin-based chemotherapy is well tolerated and associated with an improved PD9 compared with i.v. carboplatin-based chemotherapy. Clinical trial number: clinicaltrials.gov, NCT01622543.", "AuthorKeywords": ["I.p. chemotherapy", "Neoadjuvant", "Ovarian cancer"], "IndexKeywords": ["Adult", "Aged", "Aged, 80 and over", "Antineoplastic Agents", "Carboplatin", "Carcinoma, Ovarian Epithelial", "Chemotherapy, Adjuvant", "Cisplatin", "Cytoreduction Surgical Procedures", "Disease-Free Survival", "Female", "Humans", "Infusions, Intravenous", "Infusions, Parenteral", "Kaplan-Meier Estimate", "Middle Aged", "Neoadjuvant Therapy", "Ovarian Neoplasms", "Paclitaxel", "Progression-Free Survival"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 1, "EID": "2-s2.0-85042559529", "SubjectAreas": [["Hematology", "MEDI", "2720"], ["Oncology", "MEDI", "2730"]], "AuthorData": {"7003694463": {"Name": "Provencher D.M.", "AuthorID": "7003694463", "AffiliationID": "120285113", "AffiliationName": "Institut du Cancer de Montr\u00e9 al, Centre de Recherche du Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9 al"}, "57214521193": {"Name": "Gallagher C.J.", "AuthorID": "57214521193", "AffiliationID": "60159931", "AffiliationName": "Barts Health NHS Trust"}, "6603176839": {"Name": "Parulekar W.R.", "AuthorID": "6603176839", "AffiliationID": "60016005", "AffiliationName": "Canadian Cancer Trials Group (CCTG), Queen's University"}, "7004698004": {"Name": "Eisenhauer E.A.", "AuthorID": "7004698004", "AffiliationID": "60016005", "AffiliationName": "Canadian Cancer Trials Group (CCTG), Queen's University"}, "57193696607": {"Name": "Winch C.", "AuthorID": "57193696607", "AffiliationID": "60016005", "AffiliationName": "Canadian Cancer Trials Group (CCTG), Queen's University"}, "57193501423": {"Name": "Tu D.", "AuthorID": "57193501423", "AffiliationID": "60016005", "AffiliationName": "Canadian Cancer Trials Group (CCTG), Queen's University"}, "7007134127": {"Name": "Ledermann J.A.", "AuthorID": "7007134127", "AffiliationID": "60022148", "AffiliationName": "University College London Cancer Institute"}, "57200881349": {"Name": "Feeney M.", "AuthorID": "57200881349", "AffiliationID": "60022148", "AffiliationName": "University College London Cancer Institute"}, "7404407261": {"Name": "Armstrong D.K.", "AuthorID": "7404407261", "AffiliationID": "60001117", "AffiliationName": "Johns Hopkins University School of Medicine"}, "7003574359": {"Name": "Brundage M.", "AuthorID": "7003574359", "AffiliationID": "106587759", "AffiliationName": "Cancer Centre of Southeastern Ontario"}, "57203258651": {"Name": "Gourley C.", "AuthorID": "57203258651", "AffiliationID": "60027272, 60012754", "AffiliationName": "Edinburgh Cancer Research UK Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh"}, "55726010000": {"Name": "Romero I.", "AuthorID": "55726010000", "AffiliationID": "60005788", "AffiliationName": "Secretaria del\u00c1 rea Cl\u00ednica de Oncolog\u00eda Ginecol\u00f3gica, Instituto Valenciano de Oncolog\u00eda"}, "22953696600": {"Name": "Gonzalez-Martin A.", "AuthorID": "22953696600", "AffiliationID": "60110913", "AffiliationName": "MD Anderson Cancer Center"}, "8853710000": {"Name": "Bessette P.", "AuthorID": "8853710000", "AffiliationID": "60009657", "AffiliationName": "Gynecologic Oncology Division, Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al"}, "7101698198": {"Name": "Gauthier P.", "AuthorID": "7101698198", "AffiliationID": "60009657", "AffiliationName": "Gynecologic Oncology Division, Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al"}, "7403484150": {"Name": "Hall M.", "AuthorID": "7403484150", "AffiliationID": "60006776", "AffiliationName": "Department of Obstetrics and Gynaecology, Mount Vernon Cancer Centre"}, "35616103100": {"Name": "Weberpals J.I.", "AuthorID": "35616103100", "AffiliationID": "60085927", "AffiliationName": "Division of Gynaecologic Oncology, The Ottawa Hospital"}, "8607731700": {"Name": "Fung-Kee-Fung M.", "AuthorID": "8607731700", "AffiliationID": "60085927", "AffiliationName": "Division of Gynaecologic Oncology, The Ottawa Hospital"}, "16444338600": {"Name": "Hall G.", "AuthorID": "16444338600", "AffiliationID": "60020454, 60023959", "AffiliationName": "Leeds Institute of Cancer and Pathology, St James's University Hospital"}, "8948084200": {"Name": "Lau S.K.", "AuthorID": "8948084200", "AffiliationID": "60089725, 60018916, 60002494", "AffiliationName": "Division of Gynecologic Oncology, Segal Cancer Center, SMBD Jewish General Hospital, McGill University"}, "17341006400": {"Name": "MacKay H.J.", "AuthorID": "17341006400", "AffiliationID": "60009588, 60029150", "AffiliationName": "Division of Medical Oncology and Hematology, Odette Cancer Centre, Sunnybrook Health Sciences Centre"}}}